Clinical trial Recruiting at 1 site Interventional

Transaxillary TAVR guided only by echocardiography

Official title: Transaxillary Transcatheter Aortic Valve Replacement With Pure Echocardiography Guidance

Run by Chinese Academy of Medical Sciences, Fuwai Hospital · NCT07035847 · Data updated 2026-11-12

This tests whether doing transaxillary TAVR using only echocardiography is safe and practical for people with severe aortic stenosis who are suitable for axillary access.

Quick facts

Study typeInterventional
SexAll
Enrollment20 (estimated)
SponsorChinese Academy of Medical Sciences, Fuwai Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedOctober 1, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 27, 2026
Trial IDNCT07035847 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people with symptomatic severe aortic stenosis who meet the echocardiographic severity criteria and are anatomically suitable for transaxillary access without need for other concomitant cardiac interventions.

Probably not a fit

Patients who have had prior aortic valve replacement, require concomitant cardiac procedures, have untreated significant proximal coronary disease amenable to revascularization, or are inoperable due to extremely high surgical risk are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional protocol performs transaxillary transcatheter aortic valve replacement using only echocardiographic imaging for intraprocedural guidance without routine fluoroscopy or contrast angiography. Eligible patients have symptomatic severe aortic stenosis by Doppler criteria and are anatomically suitable for axillary access. The team will record procedural success, intraprocedural and perioperative complications, valve function on follow-up echocardiography, and short-term clinical outcomes. The approach aims to define the feasibility and safety profile of sole echocardiography guidance in selected patients.

Why it matters

Potential benefit: If successful, this approach could enable TAVR without radiation or iodinated contrast, which may reduce kidney injury risk and simplify imaging needs in selected patients.

How similar studies have gone: Transaxillary access for TAVR is an established route, but performing the entire procedure guided solely by echocardiography is relatively novel with only limited case series and no large-scale evidence so far.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2)
2. suitable for Transaxillary TAVR

Exclusion Criteria:

1. required hybrid procedures or concomitant interventions on other cardiac malformations
2. inoperable due to extremely high surgical risk or severe comorbidities
3. untreated clinically significant (\>70% obstruction) proximal vessel coronary vascular disease amenable to revascularization
4. previously undergone aortic valve replacement.

Where it's running

  • Fuwai Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.